Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 27th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Bausch Health Companies Inc ended up being:
In the past 5.77 years, Bausch Health Companies Inc has a compound free cash flow growth rate of 0.01%; that's higher than just 20.99% of free cash flow generating stocks in the Healthcare sector.
21% of the company's capital comes from equity, which is greater than merely 9.48% of stocks in our cash flow based forecasting set.
Bausch Health Companies Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.18. This coverage rate is greater than that of merely 20.18% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ZBH, ABT, BIO, ENZ, and TMO can be thought of as valuation peers to BHC, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
LAVAL, Quebec, May 21, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate…
LAVAL, Quebec, May 11, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1,500,000,000 aggregate principal amount of 6.250% senior notes due 2029 (the…